International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study
- 16 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (3), 503-511
- https://doi.org/10.1093/ndt/gfaa064
Abstract
Background. People with chronic kidney disease (CKD) are at high risk of polypharmacy. However, no previous study has investigated international prescribing patterns in this group. This article aims to examine prescribing and polypharmacy patterns among older people with advanced CKD across the countries involved in the European Quality (EQUAL) study. Methods. The EQUAL study is an international prospective cohort study of patients >= 65 years of age with advanced CKD. Baseline demographic, clinical and medication data were analysed and reported descriptively. Polypharmacy was defined as >= 5 medications and hyperpolypharmacy as >= 10. Univariable and multivariable linear regressions were used to determine associations between country and the number of prescribed medications. Univariable and multivariable logistic regression were used to determine associations between country and hyperpolypharmacy. Results. Of the 1317 participants from five European countries, 91% were experiencing polypharmacy and 43% were experiencing hyperpolypharmacy. Cardiovascular medications were the most prescribed medications (mean 3.5 per person). There were international differences in prescribing, with significantly greater hyperpolypharmacy in Germany {odds ratio (OR) 2.75 [95% confidence interval (CI) 1.73-4.37]; P < 0.001, reference group UK}, the Netherlands [OR 1.91 (95% CI 1.32-2.76); P = 0.001] and Italy [OR 1.57 (95% CI 1.15-2.15); P = 0.004]. People in Poland experienced the least hyperpolypharmacy [OR 0.39 (95% CI 0.17-0.87); P = 0.021]. Conclusions. Hyperpolypharmacy is common among older people with advanced CKD, with significant international differences in the number of medications prescribed. Practice variation may represent a lack of consensus regarding appropriate prescribing for this high-risk group for whom pharmacological treatment has great potential for harm as well as benefit.Funding Information
- ERA-EDTA
- Swedish Medical Association
- Stockholm County Council ALF and CIMED
- Njurfonden
- Italian Society of Nephrology
- Dutch Kidney Foundation (SB 142)
- Germany and the National Institute for Health Research in the UK
This publication has 42 references indexed in Scilit:
- New primary renal diagnosis codes for the ERA-EDTANephrology Dialysis Transplantation, 2012
- The EQUAL study: a European study in chronic kidney disease stage 4 patientsNephrology Dialysis Transplantation, 2012
- The Ethics and Reality of Rationing in MedicineSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2011
- Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in AustriaWiener klinische Wochenschrift, 2008
- Confounding: What it is and how to deal with itKidney International, 2008
- Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration RateAnnals of Internal Medicine, 2006
- Relationship of Medication Use to Health-Related Quality of Life Among a Group of Older American IndiansJournal of Applied Gerontology, 2006
- Medication Non-Adherence in the ElderlyDrugs & Aging, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987